Aerie Pharmaceuticals to be sold for $770M

Alcon, a Switzerland-based eye care company, is teed up to acquire Durham, N.C.-based Aerie Pharmaceuticals for about $770 million after approval from each company's board of directors Aug. 22. 

Aerie Pharmaceuticals specializes in testing, manufacturing and selling eye treatments. 

Pending stockholder approval, the transaction is expected to finalize in the fourth quarter of 2022, according to a news release.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars